Media Articles Related to Recombivax HB (Hepatitis B Vaccine)
Hepatitis B vaccine less effective in rheumatoid arthritis patients
Source: Arthritis / Rheumatology News From Medical News Today [2015.06.15]
The results of a study presented at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that people with rheumatoid arthritis (RA) are less likely to be...
Morning Break: Manning Up for Pizza, California Gets Tough on Vaccinations
Source: MedPageToday.com - medical news plus CME for physicians [2015.06.26]
(MedPage Today) -- Health news and commentary from around the Web, gathered by the MedPage Today staff.
New and innovative approach for successful vaccination against Chlamydia infections
Source: Immune System / Vaccines News From Medical News Today [2015.06.25]
Chlamydiae are the most common, sexually transmitted, bacterial pathogens in the world.
Tracking System Increases Hepatitis Vaccination Rates
Source: Medscape Gastroenterology Headlines [2015.06.22]
Rates of hepatitis A and hepatitis B vaccination improved significantly in patients on a liver transplant list after a nurse-led intervention was implemented.
Medscape Medical News
HPV Vaccination Tied to Drop in Precancerous Cervical Lesions in U.S.
Source: MedicineNet Cervical Cancer Specialty [2015.06.22]
Title: HPV Vaccination Tied to Drop in Precancerous Cervical Lesions in U.S.
Category: Health News
Created: 6/22/2015 12:00:00 AM
Last Editorial Review: 6/22/2015 12:00:00 AM
Published Studies Related to Recombivax HB (Hepatitis B Vaccine)
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants. [2011.07]
BACKGROUND: A modified process hepatitis B vaccine (mpHBV) uses higher phosphate content in the manufacturing process relative to the current product, Recombivax-HB. The higher phosphate is thought to improve antigen presentation, and thereby, increase antibody production. The mpHBV was previously shown to be well tolerated and immunogenic in adults. The current study tested a 2-, 4-, 6-month vaccination schedule and a higher dose formulation (10 mug mpHBV) in healthy infants... CONCLUSIONS: All 4 hepatitis B vaccines elicited high anti-HBs SPRs. After dose 3, anti-HBs GMT were highest in the 10 mug mpHBV group, but did not meet the predefined criteria for superiority. All vaccines were well tolerated.
Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. [2011.06]
BACKGROUND AND AIMS: Assessment of a new, fully liquid, investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim, Sanofi Pasteur), containing the same active ingredients as Pentaxim (DTaP-IPV//PRT-T) and 10 mug Hansenula polymorpha-derived recombinant hepatitis B (Hep B) surface antigen, Sanofi Pasteur, in Argentinean infants... CONCLUSIONS: The new, fully liquid, investigational DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim) is highly immunogenic and safe when compared with licensed comparators, warranting further development.
Effect of high-flux hemodialysis on delayed hepatitis B virus vaccination response in hemodialysis patients. [2011.05]
OBJECTIVES: The aim of the study was to evaluate the effect of high-flux (HF) hemodialysis (HD) on delayed protective hepatitis B virus (HBV) antibody seroconversion in HD patients who had no response to the classic third dose of HBV vaccination... CONCLUSION: Hemodialysis patients who do not respond to the classic third dose of HBV vaccination could reobtain a delayed higher protective HBV antibody seroconversion rate by HF HD without other intervention.
Vaccination against hepatitis B among prisoners in Iran: accelerated vs. classic vaccination. [2011.05]
BACKGROUND: Prisoners and injecting drug users are at constant risk of hepatitis B virus (HBV) infection and the classic 6-months HBV vaccination might not provide immunization rapidly enough. In this randomized clinical trial we investigated the efficacy of an accelerated vaccination protocol vs. classic schedule among prisoners in Iran... CONCLUSION: Compared to classic HBV vaccination regimen, an accelerated 0, 1, 4 and 8 weeks vaccination schedule can achieve early seroprotection more rapidly, provides clinically sufficient seroprotection with higher compliance in prisoners and can be suggested in situations that rapid immunization against HBV infection is warranted. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. [2011.04.13]
CONTEXT: Alternative schedules more immunogenic than the standard hepatitis B vaccine regimen are needed in patients with human immunodeficiency virus 1 (HIV-1) infection. OBJECTIVE: To compare the safety and immunogenicity of 4 intramuscular double-dose and 4 intradermal low-dose regimens vs the standard hepatitis B vaccine regimen... CONCLUSION: In adults with HIV-1, both the 4 intramuscular double-dose regimen and the 4 intradermal low-dose regimen improved serological response compared with the standard HBV vaccine regimen. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00480792.
Clinical Trials Related to Recombivax HB (Hepatitis B Vaccine)
Effectiveness of Two Hepatitis B Vaccines in HIV-Negative Youths [Active, not recruiting]
This study will evaluate 2 licensed vaccine products (Recombivax and Twinrix) given in a
two-dose schedule to youth at risk for hepatitis B and HIV infection to evaluate
immunogenicity of the products in this population, barriers to vaccine delivery, and factors
which predict a diminished immune response. Since these youths are also potential candidates
for future HIV vaccine trials, this study will also include preliminary assessment of youths'
understanding of informed consent forms, and willingness to participate in a vaccine trial
and return for multiple visits (including blood draws for immunologic assessment).
Immunologic Memory (Supp. of ATN 024) [Completed]
This is an exploratory, laboratory-based evaluation of cellular immune response to
immunization with hepatitis B surface antigen in HIV-infected and HIV-uninfected adolescents.
This is a substudy of ATN 024 and ATN 025. This substudy will compare cellular immune
response in responders and nonresponders to immunization and also evaluate the relationship
of these factors to the persistence of known correlates of serologic protection for the
hepatitis B virus.
Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062) [Not yet recruiting]
This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX-II
compared with the 1XP HEPTAVAX-II in healthy Japanese young adults.
Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers [Recruiting]
Vaccines have been responsible for preventing millions of deaths and extending the average
human lifespan. Effective vaccines stimulate the cells of the immune system to activate
genes and associated functions that bring about protective immunity. Knowledge of those
genes and cellular functions activated by effective vaccination can improve our
understanding of how the immune system works and define the features necessary for a
successful vaccine response. This study aims to define cellular functions important for the
hepatitis B (HBV) vaccine immune response in healthy individuals. The investigators will
identify those genes that are activated or suppressed in immune cells at various times after
each dose of the HBV vaccine. The investigators will explore these vaccine-induced "gene
signatures" to characterize the cellular functions associated with an effective immune
response to HBV vaccination. The investigators hypothesize that many genes associated with
innate and adaptive immune functions are important for an effective HBV vaccine response.
The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults [Recruiting]
Vaccines are one of our most effective public health tools but many who need them don't
respond well and are not protected. Adjuvants boost immune responses and are commonly
included in vaccine preparations. Bisphosphonates are the most commonly prescribed treatment
for osteoporosis and may represent a new class of adjuvant. Bisphosphonates are well
tolerated with chronic administration and have very few adverse effects. Research suggests
that these medications can stimulate the immune system.
Bisphosphonates are of special interest in populations with impaired immunity and an
inability to amount protective antibody responses following immunizations. We propose a
pilot study to evaluate the clinical relevance of this finding in humans. We will study the
effect of bisphosphonates on quantitative humoral immune response to hepatitis B vaccine in
healthy older volunteers who have not previously received this vaccine.